Dashboard
Analysis
Charting
Screener
Resources
Settings
NYSE-PFE
Dec '12
Dec '14
Dec '16
Dec '18
Dec '20
Dec '22
Dec '24
Primary Care Revenue
27,793
30,135
30,799
Specialty Care Revenue
17,214
16,652
14,988
Oncology Revenue
16,462
15,612
12,450
Global Pharmaceuticals Business (Biopharma) Revenue
61,469
62,400
58,237
Business Innovation (Pfizer CentreOne) Revenue
1,255
1,146
1,272
Other Revenue
61
81
44
Total Revenue
62,785
63,627
59,553
United States Revenue
37,180
38,691
28,145
Developed Markets Revenue
16,550
16,057
20,910
Emerging Markets Revenue (Post-FY2023 Reporting)
9,055
8,879
10,498
Other Revenue by Geography
—
Total Revenue by Geography
Developed Europe Revenue
11,650
Developed Rest of World Revenue
7,761
Emerging Markets Revenue
11,996
International Revenue
25,605
24,936
31,408
Global Pharmaceuticals Business (Biopharma) Earnings
28,804
28,139
15,923
Other Business Activities Earnings
-8,166
-7,382
-4,342
Other EBT
-11,485
-12,734
-10,524
Total EBT
9,153
8,023
1,057
Comirnaty Direct Sales and Alliance Revenue
5,480
5,353
11,220
Eliquis Alliance Revenue and Direct Sales
7,773
7,366
6,747
Prevnar Revenue
6,440
Paxlovid Revenue
2,870
5,716
1,279
Prevnar Family Revenue
6,343
6,411
6,501
Nurtec ODT/Vydura Revenue
1,411
1,263
928
Abrysvo Revenue
751
755
890
Vyndaqel Family Revenue
6,236
5,451
3,321
Xeljanz Revenue
1,113
1,168
1,703
Ibrance Revenue
4,178
4,367
4,753
Consumer Healthcare Revenue
Vaccines Revenue
Internal Medicine Revenue
Hospital Revenue
Inflammation & Immunology Revenue
Rare Disease Revenue